Organogenesis (NASDAQ:ORGO) Receives “Buy” Rating from BTIG Research

Organogenesis (NASDAQ:ORGO)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research note issued to investors on Thursday,Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s target price would indicate a potential upside of 227.87% from the stock’s previous close.

A number of other equities research analysts have also recently commented on ORGO. Weiss Ratings upgraded shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. Wall Street Zen raised Organogenesis from a “hold” rating to a “buy” rating in a report on Sunday, March 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Organogenesis Stock Performance

Shares of ORGO opened at $2.44 on Thursday. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04. The business has a 50-day simple moving average of $3.42 and a two-hundred day simple moving average of $4.31. The stock has a market cap of $313.88 million, a price-to-earnings ratio of 30.50 and a beta of 1.43. Organogenesis has a 52 week low of $2.31 and a 52 week high of $7.08.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%.The firm had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. On average, analysts expect that Organogenesis will post -0.07 EPS for the current year.

Insider Transactions at Organogenesis

In related news, Director Michael Joseph Driscoll acquired 10,000 shares of Organogenesis stock in a transaction dated Monday, March 9th. The shares were purchased at an average price of $2.67 per share, for a total transaction of $26,700.00. Following the completion of the transaction, the director directly owned 225,707 shares in the company, valued at approximately $602,637.69. This represents a 4.64% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 33.00% of the stock is currently owned by company insiders.

Institutional Trading of Organogenesis

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC boosted its holdings in shares of Organogenesis by 10.6% during the 3rd quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock valued at $31,641,000 after purchasing an additional 720,748 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Organogenesis by 14.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after buying an additional 680,392 shares during the last quarter. Deutsche Bank AG boosted its stake in Organogenesis by 0.4% during the fourth quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after buying an additional 13,301 shares during the last quarter. Geode Capital Management LLC grew its holdings in Organogenesis by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock valued at $9,259,000 after buying an additional 62,346 shares in the last quarter. Finally, Norges Bank bought a new stake in Organogenesis in the 4th quarter worth approximately $5,686,000. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.